N
Noden Pharma
Specializing in the acquisition, development, and commercialization of prescription medicines for niche markets
About Noden Pharma
Noden Pharma DAC is a pharmaceutical company focused on the acquisition, development, and commercialization of prescription medicines. The company primarily serves niche markets, targeting specific therapeutic areas that are often underserved by larger pharmaceutical companies. Noden Pharma operates within the global pharmaceutical industry, leveraging its expertise to identify and acquire established products that have significant market potential but may lack the necessary commercial focus from their original developers.
The business model of Noden Pharma involves acquiring rights to established pharmaceutical products and then optimizing their market presence through strategic marketing and distribution efforts. This approach allows the company to generate revenue by revitalizing and expanding the market reach of these products. Noden Pharma's clients include healthcare providers, pharmacies, and hospitals that require specialized medications for their patients.
Noden Pharma makes money through the sales of its acquired and developed pharmaceutical products. By focusing on niche markets, the company can achieve higher margins and establish a strong market presence without the intense competition faced by more generalized pharmaceutical companies. The company is also committed to sustainability and ethical business practices, aiming to be a top performer in sustainability within its industry.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Dublin, Ireland
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 36.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| BUYOUTOther financing | Jul 2020 | $0 | — | Stanley Capital | — |
| LATE VCOther financing | May 2016 | $107M | $428M | PDL Biopharma | ↗ |
Growth signals
Latest recorded traffic for Noden Pharma is 20 monthly website visits, down 94.9% over the last three months. Noden Pharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
PDL Biopharma
Stanley Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Noden Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Noden Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.